AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Kyntra Bio, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SN7DS0
4.58▼ 0.64 (-12.26%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
5.22
Day's Range
4.56 – 5.09
52-Week Range
4.56 – 9.70
Volume
43.9K
Avg Volume
25.3K
Share Statistics
Shares Outstanding
Employees
34
Exchange
XNAS
Listed
2014-11-14
Share count as of July 31, 2026

Kyntra Bio, Inc. Common Stock (KYNB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Kyntra Bio, Inc. Common Stock (KYNB)
What is Kyntra Bio, Inc. Common Stock's Market Cap?
Kyntra Bio, Inc. Common Stock's Market Cap is $18.5M, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's Trailing P/E?
Kyntra Bio, Inc. Common Stock's Trailing P/E is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's Price / Sales?
Kyntra Bio, Inc. Common Stock's Price / Sales is 4.0×, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's Revenue (TTM)?
Kyntra Bio, Inc. Common Stock's Revenue (TTM) is $4.6M, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's Net Income (TTM)?
Kyntra Bio, Inc. Common Stock's Net Income (TTM) is $183.2M, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's EBITDA?
Kyntra Bio, Inc. Common Stock's EBITDA is -$50.1M, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's Diluted EPS (TTM)?
Kyntra Bio, Inc. Common Stock's Diluted EPS (TTM) is 45.24, based on as-reported figures from SEC (XBRL) filings.
What is Kyntra Bio, Inc. Common Stock's EBITDA Margin?
Kyntra Bio, Inc. Common Stock's EBITDA Margin is -1086.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KYNBAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-209.3%+36.5%-59.3%+774.8%
Operating costs and expenses:
Cost of goods sold
Research and development
General and administrative————
Selling, general and administrative
Restructuring charge
Total operating costs and expenses
% of revenue-1092.3%469.7%1158.1%602.9%
Loss from operations
% of revenue1192.3%-369.7%-1058.1%-502.9%
Interest and other, net
Interest expense
Gain on deconsolidation of subsidiary———
Loss on debt extinguishments——
Interest income and other income (expenses), net
Total interest and other, net
Income (loss) from continuing operations before income taxes
Benefit from income taxes
Income (loss) from continuing operations
Income (loss) from discontinued operations, net of tax
Net income (loss)
% of revenue-812.3%-406.6%-1113.5%18646.5%
Net income (loss) per share - basic
Net income (loss) per share - diluted